🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to scientists.

An International Health Concern

Cases of gonorrhoea are escalating globally, with estimates suggesting more than 82 million new cases per year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the face of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Global Access

As per findings published in a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which uses a dual-drug approach. The study involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Doctors treating patients have shared positive views. Having a single-dose, oral treatment like this is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to reduce the burden of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.